Whats Happening With PFE Stock?

That being said, Oppenheimer believes that a sustained rebound isn’t yet in place. As per the strategist, the valuations are required to adjust further before equities can shift into the “hope” phase of the next cycle. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. Within the past year, PFE’s PEG has been as high as 1.24 and as low as 0.56, with a median of 0.97. If you asked me a month ago, I would have called this stock a buy.

Financial Performance

China and Japan make how to start investing on your own up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state. Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver injury. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination Overtime to break down the details, as well as preview what to watch as Johnson & Johnson (JNJ) prepares to report earnings.

Discover which analysts rank highest on spinning top candlestick predicting the directional movement of PFE. Unlock stock picks and a broker-level newsfeed that powers Wall Street.

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron. U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future. Dr. Scott Gottlieb, former FDA Commissioner, joins ‘Squawk Box’ to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.

In 2023, it earned FDA approval for nine new drugs and last year it reported over a dozen product approvals from the agency. With plenty of new products coming online, Pfizer had a good chance to overcome upcoming patent cliffs and maintain its dividend-raising streak. Many investors expect pharmaceutical industry lobbyists to prevent the Trump administration from rendering CDER incapable of reviewing new drug applications at its usual pace. They could be right, but I won’t support an investment thesis that relies on industry lobbyists protecting a regulatory agency. A disappointing outcome for a weight-management candidate isn’t anywhere near the top of Pfizer’s list of problems. Investors should be far more concerned with an upcoming loss of patent-protected market exclusivity for Eliquis.

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?

According to reporting from STAT, more than a few FDA employees involved in the new drug approval process were among thousands recently fired from the agency. Drug developers need to communicate with regulators at the Food and Drug Administration (FDA) before, during, and after they run clinical trials for new drug candidates. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties… Nine out of ten “Safest” BBB dividend dogs are ready to buy, with annual dividends from $1K invested exceeding single share prices. Analysts expect 32.86% to 53.48% net gains from top-ten BBB dogs by …

• In addition, the company involved in the contract manufacturing business.
• On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits.
• With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
• The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.
• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began.

Is Pfizer (PFE) Stock Undervalued Right Now?

Select to analyse similar companies using key performance metrics; select up to four stocks. Next, we chose the stocks that trade at a forward P/E of less than ~20.0x. Finally, the stocks are arranged in ascending order of the hedge fund sentiments, as of Q4 2024. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

• The Prevnar family of vaccines was responsible for over 10% of total sales last year.
• (0.18%), Rhumbline Advisers (0.17%), Fifth Third Bancorp (0.05%) and Wealth Enhancement Advisory Services LLC (0.05%).
• Bridge Bio and Alnylam are now marketing competing treatments for the limited population of TTR amyloidosis patients with heart damage.

Top Ranked Stocks in Industry

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits. While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Vyndaqel has been a strong growth driver for Pfizer but probably not for much longer. This treatment prevents heart damage caused by transthyretin (TTR) amyloidosis and grew sales by 64% to reach $5.4 billion last year.

Discover which analysts rank highest for PFE overall weighted by direction, price target, and price movement. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. A crippled FDA could be a huge problem for Pfizer and its peers who must constantly launch new drugs to overcome exclusivity losses for established products. Having the former CDER director on staff could be advantageous for Pfizer, but I’ll be pleasantly surprised if the FDA completes new drug approvals at coinberry review half the usual pace this year.

It was the first mass producer of the “miracle drug” penicillin in the 1940s and was generating more than a billion dollars in sales by the early 1970s. Pfizer has become one of the biggest pharmaceutical companies in the world, with a market capitalization of $251.3 billion as of Nov. 3, 2021. Value investors will likely look at more than just these metrics, but the above data helps show that Pfizer is likely undervalued currently. And when considering the strength of its earnings outlook, PFE sticks out at as one of the market’s strongest value stocks. Value investors also love the P/S ratio, which is calculated by simply dividing a stock’s price with the company’s sales. Some people prefer this metric because sales are harder to manipulate on an income statement.

Danuglipron was the latest drug investors were hinging hope on to enter the obesity market. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Top institutional shareholders of Pfizer include Assenagon Asset Management S.A.

Pfizer (PFE) said it will stop development of an oral daily weight-loss pill after a participant taking the drug in a clinical trial experienced a liver injury. Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue.

By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup. Select to analyze similar companies using key performance metrics; select up to 4 stocks. Please bear with us as we address this and restore your personalised lists.